leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Nanomedicine 2006-2011

Nanomedicine 2006-2011

  • Publication date: 29/06/2006
  • Number of Pages: 147
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

The purpose of this Visiongain report is to examine the commercial prospects of nanotechnology in medicine – the fast-developing and increasingly lucrative field of nanomedicine. Nanotechnology has great potential to benefit - even revolutionise - the pharmaceutical, medical devices, diagnostics and imaging sectors. Visiongain predicts that nanomedicine will exhibit strong growth in all sectors from 2006-2011, leading to multi-billion dollar revenues. Key technology platforms such as nanocrystals, nanotubes, dendrimers, fullerenes, quantum dots and molecular scaffolding will drive that market expansion.

Nanomedicine 2006-2011 examines the nanomedical sector critically through comprehensive primary and secondary research, including interviews with key figures in industry and academia, reports and policy documents, nanotechnology conference proceedings, business/industry news and consultation with bodies promoting nanotechnology. Visiongain applied techniques such as financial forecasting, SWOT analysis and qualitative projections to provide a comprehensive market report with detailed analyses and informed opinion.

In particular, this report concentrates on the following essential aspects of nanotechnology in the healthcare industry:

  • Technologies that drive nanomedicine
  • Key players in nanomedicine
  • Revenue trends for nanotechnology in healthcare between 2006-2011
  • Projected timetables for major developments up to 2020
  • Drivers and opportunities in nanomedicine
  • Restraints and threats in nanomedicine
  • Funding and governmental policy in nanomedicine
  • Venture capital in nanomedicine
  • Regulation, safety and ethics of nanotechnology in medicine
  • An assessment of relevant business models and issues
  • A geographical breakdown of the world market for nanomedicine in 2011

Why you should buy this report

  • To receive a comprehensive analysis of the prospects of the world nanomedical sector from 2006-2011
  • To find out predicted revenues, growth rates and market shares for sectors within nanomedicine from 2006-2011
  • To determine the forces that influence nanotechnology with medical applications:
  • Competitive characteristics of the market
  • Regulatory, funding and societal issues
    Drivers and restraints
  • Strengths, weaknesses, opportunities and threats
  • To find out where nanotechnology in medicine is heading - both technologically and commercially - in the mid-to-long-term periods as well

Table of Contents

1. Executive Summary - Nanomedicine Will Constitute One of the Most Exciting and Fast Growing Aspects of Medicine

2. An Introduction to Nanotechnology with Medical Applications
2.1  What is Nanotechnology? - An Introduction to this Exciting Interdisciplinary Field
2.1.1  Top-down and Bottom-up Approaches to Nanotechnology
2.1.2  Terminology and Definitions in Nanotechnology Are Still Not Universally Accepted
2.1.3 This Report Highlights the Commercial Potential for Nanotechnology in Healthcare   
2.2  What Solutions and Improved Performance Can Medical Nanotechnology Provide?
2.2.1  Improving Drug Delivery
2.2.2  Biomedical Devices
2.2.3  Imaging and Diagnostics
2.2.4  Tissue Reconstruction
2.3  Nanotechnology and its Applications in Healthcare - An Overview of Emerging Technologies
2.3.1  Molecular Assembly - Is this the Holy Grail of Nanomedicine?
2.4  Nano-Level Microscopy and Related Technologies Constitute Important Tools in Medicine - Particularly Genomic and Proteomic Drug Discovery
2.4.1  Scanning Tunnel and Scanning Probe Microscopy
2.4.2  Atomic Force Microscopy
2.4.3  Cantilever Arrays in Atomic Force Microscopy Have Relevance to Proteomics
2.4.4  Lithography at the Nanoscale - Medical Devices Could Benefit
2.4.5  Nanopore Technology Can Detect Single Molecules
2.5  Nanoparticles 
2.5.1  Nanoparticluate technologies with Injectable and Topical Uses
2.5.2  Nanocrystals and Other Nanoparticles in Nanomedicine and Immunohistochemistry
2.5.3  Drug Delivery - Improved Bio-availability through Nanocrystals and Other Nanoparticles
2.5.4  Quantum Dots
2.5.5  Bioconjugates Formed from Quantum Dots
2.5.6  Dendrimers
2.5.7  Nanoshells 
2.5.8  Magnetic Nanoparticles
2.5.9  Gold Colloids
2.5.10  DNA Detection Via Nanoparticle-Based Colourimetric Methods
2.5.11  Rexin G - An FDA-approved Nanoparticle Delivery System
2.6  Improved Detection Sensitivity with Carbon Nanotubes and Nanotube Matrices
2.7  Nanobarcodes
2.8  Liposomes
2.9  The Use of Fullerenes (Buckyballs) in Drug Delivery
2.9.1  Gadolinium in Fullerenes and QDs as MRI Agents
2.10  Nanowires
2.11 RNA-based Drug Delivery
2.12  Nano-enabled Tissue Engineering and Bone Implants
2.13  Nanodiagnostics
2.13.1  Nanotechnologies with Biochips and Protein Chips
2.13.2  Lab-on-a-chip Technology Incorporating Microfluidics and Nanofluidics
2.13.3  Resonance Light Scattering and Surface Plasmon Resonance Technologies
2.14  Nanobiosensors
2.14.1  Boron-doped Silicon Nanowires as Biosensors
2.14.2  Viral Nanosensors
2.14.3  Probes Encapsulated by Biologically Localised Embedding Nanosensors
2.14.4  New Nano-based Biosensor Technologies in Market
2.15 Nanoparticles Are Likely to Constitute the Most Successful Aspect of Nanomedicine from 2006-2011

3. Key Players in the Nanomedical Sector
3.1  Key Players in the Current Nanomedical Sector - An Overview
3.2  Leading Companies in Nanoparticle Technology
3.3  Case Study - Elan Drug Technologies' NanoCrystal  Platform
3.3.1  Wyeth's Rapamune
3.3.2  Merck's Emend
3.3.3  Par Pharmaceutical's Megace ES
3.4  Leaders in Cancer Therapies Incorporating Nanotechnology
3.5  Leading Suppliers of Dendrimer, Fullerene and Nanotube Technologies for Medicine
3.5.1  Starpharma is a Leader in Dendrimer Technology
3.6  Leading Diagnostics and Imaging Companies in Nanomedicine

4. Forecasts of the World Nanomedical Market
4.1  The World Nanomedical Market Will Exhibit Strong Growth from 2006-2011
4.2  The Pharmaceutical Sector Will Contribute the Most Revenues to Nanomedicine
4.3  Nanotechnology Use in Medical Devices Will Also Contribute Heavily to Overall Revenues in Nanomedicine
4.4  The US Will Continue to Lead the World Market for Nanomedicine
4.5  Developmental Trends in Nanomedicine with their Timelines
4.5.1  Many Important Developments Will Occur Between 2010 and 2020
4.5.2  The European Science Foundation Outlines Important Future Developments in Nanomedicine
4.5.3  Drug Discovery and Drug Delivery Are Likely to Benefit Most from Nanotechnology
4.5.4  Diagnostic Applications Will Also Be Major Components of Nanomedicine
4.5.5  Tissue Engineering Will Show Exciting Promise
4.6  The US National Science Foundation (NSF) Predicts Spectacular Growth In Revenues

5. An Analysis of Factors that Influence the Market for Nanomedicine
5.1  SWOT Analysis of Nanotechnology in Medicine
5.2  The Nanomedical Sector Will Continue To Expand its Presence in the Healthcare Industry
5.3  This Emerging Field Contains Uncertainty and Further Potential for Controversy
5.4  Governmental Funding Constitutes a Major Driver of Nanomedicine
5.4.1  The US, European and Japanese Governments are Leading Public Investors in Nanotechnology
5.4.2  The US National Nanotechnology Initiative (NNI) Contributes Large Amounts of Funding to Nanomedicine
5.4.3  The US National Institutes of Health (NIH) Roadmap for Medical Research Will Secure Continued Public Funding for Nanomedicine
5.4.4  Japan is the Second Largest Investor in Nanotechnology
5.4.5  The EU is also a Large Sponsor of Nanomedicine
5.4.6  European Governments Support Nanotechnological Research
5.5  Venture Capitalism in Nanomedicine
5.5.1  Nanotechnology is Currently Attractive to Private Investors
5.5.2  Nanotechnological Investments Hold Risks
5.5.3  Will Nanotechnology Lead to Another High-tech Bubble?
5.5.4  Nanomedicine Receives an Estimated 40% of Private Investment for Nanotechnology
5.5.5  Revolutionary Developments in Nanomedicine Will Require Long Term Investment
5.5.6  A Survival-of-the-fittest Process is Emerging in Nanomedical Investment
5.5.7 There is an Urgent Need for Nanomedicine to Justify Large-scale Public and Private Investment Through Marketable Products
5.6  Interdisciplinary Activity Benefits Nanomedicine
5.7  Regulatory Issues in Nanomedicine
5.7.1  The FDA Uses Standard Risk Management to Assess Nanotechnological Products
5.7.2  The FDA Regulates Products, Not Technology
5.7.3  The FDA is Currently Formulating Policy for the Appraisal of Nanotechnology
5.7.4  Nanotechnology Features in the FDA Critical Path Initiative
5.7.5  The FDA's Nanotechnology Interest Group
5.7.6  The FDA Predicts Regulatory Overlaps Between Pharmaceuticals, Medical Devices and Biologicals
5.7.7  The European Medicines Agency (EMEA) Stance on Nanomedicine
5.7.8  Visiongain's Assessment of Regulatory Trends in Nanomedicine
5.8  Specific Concerns Relating to the Safety of Nanoparticles in Health and the Environment
5.8.1  Few Conclusive Toxicological Studies Have Been Performed on Nanomaterials
5.8.2  Continuing Uncertainty About Effects of Nano-scale Materials on Health and Environmental Safety
5.8.3  Selenium, Lead and Cadmium Elicit Particular Concerns
5.8.4  Concerns Over Fullerenes and Dendrimers
5.8.5  Nanoparticles May Cause Pulmonary Damage
5.8.6  Ability of Nanoparticles to Penetrate Cells May Constitute a Double-edged Sword
5.9  Societal and Ethical Aspects of Nanomedicine
5.9.1  A Balanced Portrayal of Nanotechnology by Governments and the Media is Required
5.9.2 Nanomedicine Has the Potential to Change the Way Medicine is Practised
5.9.3  Ethical Concerns Relating to Nanomedicine
5.9.4  Communication with All Relevant Stakeholders is Required
5.9.5  Nanomedicine Cannot Afford to Repeat the PR Mistakes of Biotechnology
5.9.6  The Healthcare Industry Needs to Promote Nanomedicine to Society in a Credible, Transparent Manner
5.9.7  Civil Liberties and Benefits to the Developing World
5.9.8  Is Nanotechnology Actually Required in Medicine?
5.10  Will Nanomaterials Have Enough Stability for Use as Effective Therapies?
5.11  Nanomedicine Benefits from Networks and Organisations that Promote Nanotechnology
5.12  Low Yields and High Costs May Hinder Nano-scale Manufacturing In the Short to Medium Term

6. Commercial Aspects of the  Nanomedicine Business Models
6.1  Pipeline Developments in Nanomedicine are Increasing Rapidly
6.2  Acquiring Nanomedical Technology Platforms from External Sources is Prevalent
6.2.1  Quantum Dot Corporation
6.2.2  Elan's NanoCrystal Technology
6.2.3  Invitrogen Acquires Nanotechnology Providers
6.2.4  Starpharma - A Leader in Dendrimer Technology
6.3 Careful Assessment of Technology Suppliers is Vital in Nanomedicine
6.4 Is the Pharmaceutical Industry Under-investing in Nanotechnology Compared with Other Leading Industrial Sectors?
6.5  Large Companies Are Often Risk-Averse: This Can Make Them Less Innovative and Adaptive to the Market
6.5.1  Cultural Gaps Between Healthcare Corporations and    Smaller Technology Providers Can Be a Problem
6.5.2  Start-up Companies Must Overcome Many Obstacles - Especially Securing Funding for Expansion
6.6  Intellectual Property Protection Will Be Vital to Success in Nanomedicine
6.6.1  Patent Offices Inundated by Patent Applications in Nanomedicine
6.6.2  Patenting Pools May Be the Answer
6.6.3  Pre-emptive Activities Benefited Elan and Baxter
6.6.4  Lack of Uniformity in Nanotechnological Terminology Causes Potential IP Problems
6.6.5  Broad Patent Claims Provide First-mover Advantages in Nanomedicine
6.6.6  Affymetrix Maintains First-mover Advantage
6.6.7  The Bayh-Dole Act Should Benefit Nanomedicine in the US
6.6.8 IP in Nanomedicine - Visiongain's Conclusions
6.7  Experts' Views on Commercial Issues in Nanomedicine
6.7.1  Companies Need to Look for "Killer" Applications for Nanotechnology in Medicine
6.8  Are Partnerships With Academia Working Well Enough in Nanomedicine?
6.9  Industrial Scale-up of Nanomedical Technology Will Constitute a Great Challenge

7. Conclusions - Nanotechnology Holds Great Promise for the Healthcare Industry with Expanding Investment, Revenues and Development
7.1  Nanotechnology Holds Great Promise in Healthcare  
7.2  The World Nanomedical Sector Will Achieve Strong Growth from 2006-2011
7.3  Despite Rapid Growth, Nanomedicine is Still in Its Infancy
7.4  Drivers in Nanomedicine Will Exert a Strong Positive Effect on the Market
7.5  There is Still Some Uncertainty and Potential Controversy Surrounding Nanomedicine
7.6  Nanomedicine Benefits from Large Amounts of Public and Private Funding
7.7  Sound IP Strategies Will be Vitally Important to the Continuing Success of Nanomedicine
7.8  Regulatory Issues Have Not Constituted a Problem So Far, But Policies Are Still Developing
7.9  Various Business Models Are Used in Nanomedicine

List of Tables

Table 2.1  Nanotechnological Applications with Potential to Benefit Healthcare
Table 2.2  Lithography as an Important Top-down Nanotechnological Tool
Table 3.1  Prominent Companies in Important Areas of Biomedicine - An Overview, 2006
Table 3.2  Launched or Recently FDA-approved Drugs Incorporating Nanoparticle Technologies, 2006
Table 3.3  Medical Applications of Nanoparticle Technology - Some Leading Companies, 2006
Table 3.4  Companies Using Nanotechnology in Oncology, 2006
Table 3.5  Leading Developers of Molecular Tags, 2006
Table 3.6  Leading Developers of Molecular Arrays, 2006
Table 4.1  World Revenues ($m) for Nanotechnology in Healthcare, 2006-2011
Table 4.2  Growth (CAGR) in World Revenues For Nanotechnology in Healthcare, 2006-2011
Table 4.3  The Proportional Contribution (%) of Nanotechnology to Total Healthcare Revenues, 2006 and 2011
Table 4.4  Contribution of Market Sectors to Nanomedical Revenues, 2006 and 2011
Table 4.5  A Breakdown of the Total 2011 Nanomedical Forecast by Nanotechnological Application
Table 4.6  Market Share (%) of the World Nanomedical Market and Revenues ($m) by Region, 2011
Table 4.7  A Timeline for Important Developments in Nanotechnology
Table 4.8  Developments in Nanomedicine: The Periods 2005-2010 and 2010-2015 Reviewed
Table 4.9  European Science Foundation (ESF) Priorities for Nanomedicine from 2005-2015
Table 4.10  Timeline for Developments in Nanotechological Targeted Drug Delivery, 2005-2015
Table 4.11  Timeline for Developments in Nanodiagnostics
Table 4.12  Timeline for Developments in Regenerative Medicine
Table 4.13  A Breakdown of the NSF Forecast for Nanotechnological Revenues ($bn) by 2015
Table 7.1 Prominent Companies in Important Areas of Biomedicine - An Overview, 2006
Table 7.2 Growth (CAGR) in World Revenues For Nanotechnology in Healthcare, 2006-2011

List of Figures

Figure 1.1 Key Areas in Nanomedicine
Figure 2.1 Nanotechnology in Perspective, with Relevance to the Life Sciences and Medicine
Figure 2.2 Top-Down and Bottom-Up Approaches in Nanomedicine
Figure 4.1 World Revenues ($m) for Nanotechnology in Healthcare, 2006-2011
Figure 4.2 CAGR (%) in World Revenues for Nanotechnology in Healthcare, 2006-2011
Figure 4.3 Contribution of Market Sectors to Overall Nanomedical Revenues, 2006 and 2011
Figure 4.4 Nanomedical Revenues ($m) by Application, 2011
Figure 4.5 Nanomedical Market Share (%) by Application, 2011
Figure 4.6 World Revenues For Nanotechnology in the Pharmaceutical Sector, 2006-2011
Figure 4.7 World Revenues For Nanotechnology in the Medical Devices Sector, 2006-2011
Figure 4.8 World Nanomedical Revenues ($m) by Region, 2011
Figure 4.9 Share of the World Nanomedical Market by Region (%), 2011
Figure 4.10 A Breakdown of the NSF Forecast for Nanotechnological Revenues by 2015
Figure 5.1 A SWOT Chart for Nanotechnology in Medicine, 2006-2011
Figure 5.2 Public Spending on Nanotechnological Development in The US, Japan and Europe, 2003
Figure 5.3a Total Worldwide Public Spending on Nanotechnological Developments, 1997-  2003
Figure 5.3b Public Spending ($m) on Nanotechnological Developments by Region, 1997-2003
Figure 5.4 US National Nanotechnology Initiative Total Investment ($m), All Agencies Combined, 2001-2007
Figure 5.5 US National Nanotechnology Initiative Spending ($m) by Agency, 2005 and 2007
Figure 5.6 US Governmental Spending ($m) on Nanotechnology in Health: NIH Funding from the NNI Budget, 2001-2007
Figure 5.7 Japanese Governmental Funding ($m) of Nanotechnological Research, 1998-2004
Figure 5.8 Global Venture Capital Investments by Sector (%), 2004
Figure 5.9 Stakeholders in Nanomedicine
Figure 6.1 Pipeline Developments in Nanomedicine, 2004-2005
Figure 7.1 World Revenues ($m) for Nanotechnology in  Healthcare, 2006-2011

Companies Listed

454 Life Sciences
Abbott Laboratories
Accusphere
Advectus Life Sciences
Advimer Therapeutics
Advion BioSciences
Aerogen
Affymetrix   
Agilent
Alnis Biosciences
Alza
Ambri Ltd
American Biosciences
American Pharmaceutical Partners
Amgen
AngstroMedica
Baxter Healthcare
Biacore
BioCrystal
BioForce Nanosciences
BioSante Pharmaceuticals
Biotrin
Bristol-Myers Squibb
C Sixty
Cambridge Diagnostics
Cellix
Cymbet
Dade Behring
Deerac Fluidics
Dendritic Nanotechnologies
Dow Chemical Company
Eastman Kodak
Eirx
Elan Pharmaceuticals
Epeius Biotechnologies
Evident Technologies  
Flamel
Fournier
Genentech
Genicon Sciences  
Georgia Tech Research Corporation
GlaxoSmithKline
Guidant
iMEDD
Immunicon
Integrated Nano-Technologies
Invitrogen
Johnson & Johnson
Life Scientific
Luxcell
Medtronic
Merck & Co.
Merrion
Midatech Group
NanoBio Corporation
Nano-C Corporation
NanoCrystal Technologies
Nanogen  
NanoGram Devices
NanoInk
NanoMaterials
NanoMed Pharmaceuticals
NanoPharm
NanoPlex 
Nanoplex Technologies
Nanospectra Biosciences
Nanosphere
Nanosys  
Novavax
Oxonica
Opsona
Par Pharmaceutical
Protiveris
Proxy Biomedical
pSiMedica
Qiagen
Quantum Dot Corporation
Sequus
SkyePharma
Spectrum Pharmaceuticals
Starpharma
Tridelta
Trinity Biotech
Triton BioSystems
US Genomics
Wyeth
Xenith Biomed

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close